Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07020832
PHASE3

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

Sponsor: Apellis Pharmaceuticals, Inc.

View on ClinicalTrials.gov

Summary

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

Official title: A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

320

Start Date

2026-02

Completion Date

2028-08

Last Updated

2026-03-13

Healthy Volunteers

No

Interventions

DRUG

Pegcetacoplan

Complement (C3) Inhibitor

OTHER

Placebo

Sterile solution of equal volume to active arm

Locations (1)

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

São Paulo, Brazil